Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Dec;2(12):711-9.
doi: 10.1038/nchembio839.

RNAi therapeutics: a potential new class of pharmaceutical drugs

David Bumcrot  1 , Muthiah Manoharan, Victor Koteliansky, Dinah W Y Sah
Affiliations
Review

RNAi therapeutics: a potential new class of pharmaceutical drugs

David Bumcrot et al. Nat Chem Biol. 2006 Dec.

Abstract

The rapid identification of highly specific and potent drug candidates continues to be a substantial challenge with traditional pharmaceutical approaches. Moreover, many targets have proven to be intractable to traditional small-molecule and protein approaches. Therapeutics based on RNA interference (RNAi) offer a powerful method for rapidly identifying specific and potent inhibitors of disease targets from all molecular classes. Numerous proof-of-concept studies in animal models of human disease demonstrate the broad potential application of RNAi therapeutics. The major challenge for successful drug development is identifying delivery strategies that can be translated to the clinic. With advances in this area and the commencement of multiple clinical trials with RNAi therapeutic candidates, a transformation in modern medicine may soon be realized.

PubMed Disclaimer

Conflict of interest statement

The authors are employees of Alnylam Pharmaceuticals.

Figures

Figure 1
Figure 1. Cellular mechanism of RNA interference.
Long double-stranded RNA (dsRNA) is cleaved, by the enzyme Dicer, into small interfering RNA (siRNA). These siRNAs are incorporated into the RNA-induced silencing complex (RISC), where the strands are separated. The RISC containing the guide or antisense strand seeks out and binds to complementary mRNA sequences. These mRNA sequences are then cleaved by Argonaute, the enzyme within the RISC responsible for mRNA degradation, which leads to mRNA down-modulation. A, adenosine.
Figure 2
Figure 2. Chemical modifications of siRNAs.
Shown are structures of sugar, backbone and base modifications and of the cholesterol conjugate.
Figure 3
Figure 3. Critical nucleotide positions in siRNAs.
Nucleotides that are important for potency, mRNA recognition, mRNA cleavage and cleavage specificity, including minimization of off-targeting, are shown.
Figure 4
Figure 4. Organs for which RNAi proof of concept has been demonstrated.
Direct RNAi represents local delivery of RNAi, and has been carried out successfully to specific tissues or organs, including lung, eye, the nervous system, tumors, the digestive system and vagina. Systemic RNAi represents intravenous delivery of RNAi and has been carried out successfully to lung, tumors, liver and joint. Specific disease models are indicated where efficacy was achieved.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541–552. doi: 10.1038/sj.gt.3302703. - DOI - PubMed
    1. Dykxhoorn DM, Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu. Rev. Biomed. Eng. 2006;8:377–402. doi: 10.1146/annurev.bioeng.8.061505.095848. - DOI - PubMed
    1. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. USA. 2004;101:14385–14389. doi: 10.1073/pnas.0405913101. - DOI - PMC - PubMed
    1. Ma JB, et al. Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature. 2005;434:666–670. doi: 10.1038/nature03514. - DOI - PMC - PubMed
    1. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 2005;123:607–620. doi: 10.1016/j.cell.2005.08.044. - DOI - PubMed